glp 1 agents Glucagon-like peptide-1 Research shows GLP-1 drugs are

2025;8(1) doi: 10.1001/jamanetworkopen.2024.57349

Here is what our research shows

The introduction of new generics and biosimilars is expected to help curb future spending by offering lower-cost alternatives to high-priced brand-name drugs.

This analysis examines specific approaches to reduce GLP-1 medication costs, including manufacturer savings programs, prescription assistance options, and alternative procurement methods

For weekly injections, official schedules use gradual dose increases so the body has time to adjust and GI side effects are less likely

Compared to the use of GLP1-RAs alone, the combination of SGLT2is and GLP1-RAs was associated with a 30% reduction in the risk of MACE, with rates of 7.0 versus 10.3 events per 1000 person-years (HR 0.70